Drugs / HRS-1167
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06198556 | Jan → Feb 2024 | neoplasm | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05473624 | Aug 2022 → Dec 2026 expected | cancer | Jiangsu HengRui Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT06689163 | Dec 2024 → Nov 2025 overdue | prostate cancer | Jiangsu HengRui Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06568094 | Sep 2024 → Dec 2026 expected | prostate cancer | Jiangsu HengRui Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06308406 | Mar 2024 → Oct 2025 | ovarian cancer | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06516289 | Sep 2024 → Jun 2026 overdue | Her2-receptor negative breast cancer | Fudan University | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-06-03 | EMD Serono Research & Development Institute, Inc. | Results Merck KGaA, Darmstadt, Germany’s Innovative Oncology Pipeline of DNA Damage Response Inhibitors and Antibody-Drug Conjugates Poised to Advance Cancer Treatment emdserono.com ↗
data presented during the 2024 ASCO Annual Meeting from Hengrui’s first-in-human clinical trial show a favorable safety profile and promising efficacy in PARP-naïve, PARP-sensitive tumors |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-06-03 | EMD Serono Research & Development Institute, Inc. | Merck KGaA, Darmstadt, Germany’s Innovative Oncology Pipeline of DNA Damage Response Inhibitors and Antibody-Drug Conjugates Poised to Advance Cancer Treatment emdserono.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HRS-1167 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06568094 ↗ |
| Action | Inhibit | “a highly selective PARP1 inhibitor” NCT06516289 ↗ |
| Route | Oral | “single oral dose of HRS-1167” NCT06198556 ↗ |